Annovis Bio, Inc. Overview
Pro stress-test →Annovis Bio is a clinical-stage drug platform company developing drugs to treat neurodegeneration, with its lead product candidate Buntanetap in phase 2/3 for Alzheimer's disease and phase 3 for Parkinson's disease. The company targets a critical unmet need in neurodegenerative disease treatment with significant clinical and commercial opportunity.
Strategic Profile
Pro stress-test →The company is on schedule for its first 6-month readout in 2026 from its pivotal Phase 3 study enrolling 760 Alzheimer's patients, with dual evaluation of symptomatic efficacy at 6 months and disease-modifying response at 18 months. Annovis is also launching an Open-Label Extension study for Parkinson's disease in January 2026 targeting 500 patients, positioning the company for potential regulatory pathway advancement.
Competitive Landscape
Pro stress-test →Annovis targets challenging neurodegenerative conditions and faces competition in Alzheimer's and Parkinson's disease markets with risks related to trial failures and FDA approval concerns. The competitive environment includes established players and emerging biotech companies developing disease-modifying and symptomatic treatments for these large markets.
Industry Context
Annovis Bio, Inc. operates in Biotechnology / Neuroscience.
Key facts
Founded: 2008 · Headquarters: Malvern, Pennsylvania · Employees: 8 · Market cap: $93M